drugset / Trial / NCT00755872

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

NCT00755872

Phase 1 Completed 76 enrolled Warner Chilcott Sanofi · collab
RandomizedCrossoverOpen-label

Summary

This is a randomized, open-label, multi-center, 4-treatment, 4-period crossover study. Approximately 72 healthy, surgically sterile or postmenopausal subjects will be enrolled and have urine collected over 72 hours following administration of risedronate for all 4 treatment periods).

Timeline

Start
2007-11
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 35 mg

Indications

No indication recorded.